Deutsche Bank Upgrades Celgene (CELG) to Buy from Hold

Friday, April 5, 8:13 AM ET

Celgene (CELG) gets an upgrade from Deutsche Bank to Buy from Hold. The bank says survey data gathered from 100 dermatologists and rheumatologists suggests Apremilast is a "blockbuster." DB raises its price target from $105 to $143. Shares +1.4% premarket.

Celgene is one of our high conviction positions in the GWM Core Equities Folio. It may have trouble bucking the down market today, but should hold up relatively well in the face of a market downturn.